In the SURMOUNT-1 clinical trial, participants taking tirzepatide lost approximately 25% of their total weight loss as lean mass and 75% as fat mass over 72 weeks — translating to a 10.9% reduction in total lean body mass and a 33.9% reduction in total fat mass from baseline [1]. In absolute terms, tirzepatide-treated participants lost an average of 5.6 kg of lean mass alongside 15.9 kg of fat mass. This 75/25 fat-to-lean ratio is consistent with what is observed in most forms of caloric restriction — it is not unique to tirzepatide or GLP-1 medications — but it means that significant weight loss inevitably involves some muscle loss unless specific countermeasures are in place [1]. The critical clinical question is not whether lean mass loss occurs, but whether it is monitored, minimized, and managed.
This article explains what the body composition data from clinical trials actually shows, how tirzepatide compares to semaglutide and other weight loss methods, what the clinical consequences of lean mass loss are, and what the evidence says about preventing it.
What the SURMOUNT-1 DXA Substudy Found
The most detailed body composition data for tirzepatide comes from a DXA (dual-energy X-ray absorptiometry) substudy within SURMOUNT-1 — the pivotal trial that led to tirzepatide's FDA approval for weight management. This substudy measured 160 participants (124 on tirzepatide, 36 on placebo) with full-body DXA scans at baseline and week 72 [1].
The results at 72 weeks:
| Measure | Tirzepatide | Placebo |
|---|---|---|
| Total weight loss | \-21.3% | \-5.3% |
| Fat mass reduction | \-33.9% | \-8.2% |
| Lean mass reduction | \-10.9% | \-2.6% |
| Visceral fat reduction | \-40.1% | \-7.3% |
In this substudy, the proportion of weight lost as fat versus lean mass was similar between tirzepatide and placebo — approximately 75% fat and 25% lean in both groups [1]. This finding suggests no clear disproportionate lean mass loss attributable to tirzepatide in this dataset, compared to what occurs during equivalent weight reduction through caloric restriction. The medication produces substantially more total weight loss, which means more absolute lean mass is lost — but the composition of that weight loss is the same as what occurs with caloric restriction alone.
By dose level, the fat-to-lean ratio was consistent across the tirzepatide 5 mg, 10 mg, and 15 mg groups — 75%, 72%, and 75% of weight lost as fat mass, respectively [1]. Higher doses did not cause a worse lean mass ratio.
A systematic review of tirzepatide's effects on skeletal muscle confirmed these findings and added data from the SURPASS-3 MRI substudy, which showed fat-free muscle volume reductions of 5.5% in men and 6.9% in women at 52 weeks — described as "small and within expected ranges" [2].
How Tirzepatide Compares to Semaglutide
The STEP 1 DEXA substudy measured body composition changes with semaglutide 2.4 mg in 140 participants over 68 weeks [3]:
| Measure | Semaglutide 2.4 mg | Tirzepatide (pooled) |
|---|---|---|
| Total weight loss | \-15.0% | \-21.3% |
| Total fat mass reduction | \-19.3% | \-33.9% |
| Total lean mass reduction | \-9.7% | \-10.9% |
| Visceral fat reduction | \-27.4% | \-40.1% |
| Lean-to-fat ratio improvement | +0.23 | Improved (comparable) |
The lean mass reduction percentages are similar — 9.7% for semaglutide versus 10.9% for tirzepatide — despite tirzepatide producing substantially more total weight loss (21.3% vs. 15.0%). This suggests that tirzepatide's additional weight loss comes predominantly from fat rather than lean tissue.
The STEP 1 substudy also reported an important nuance: while absolute lean mass decreased, the proportion of lean mass relative to total body weight actually increased by 3.0 percentage points with semaglutide [3]. The same pattern holds for tirzepatide — patients end treatment with less lean mass in absolute terms, but a higher percentage of their remaining body weight is lean tissue rather than fat.
Why Lean Mass Loss Matters Clinically
A 10.9% reduction in lean mass is not just a number on a scan — it has measurable metabolic and functional consequences:
Reduced resting metabolic rate. Muscle tissue is the primary driver of resting metabolic rate (RMR). Every kilogram of lean mass lost reduces the number of calories your body burns at rest. When a patient loses 5.6 kg of lean mass during tirzepatide treatment, their post-treatment caloric requirements are measurably lower than before. If appetite signals return to pre-treatment levels after discontinuation — which the evidence shows they do — the patient is now burning fewer calories against the same hunger drive, creating the metabolic conditions for weight regain.
Sarcopenic obesity risk. The simultaneous presence of excess fat and depleted muscle mass defines sarcopenic obesity — a condition associated with higher rates of cardiovascular disease, type 2 diabetes, disability, and mortality than either obesity or sarcopenia alone. Patients who lose significant lean mass during GLP-1 treatment without countermeasures may transition from one metabolic risk profile to another rather than improving their overall health.
Functional decline. Lean mass supports physical function — walking speed, balance, stair climbing, fall prevention. For older adults or patients with limited baseline muscle mass, a 10% reduction in lean tissue can cross the threshold from functional independence to impairment. The SURMOUNT-1 substudy noted that tirzepatide "significantly improved patient-reported physical function" despite lean mass loss [1] — but clinical trials enroll relatively healthy participants with exercise and dietary counseling. Real-world patients without those supports may not experience the same functional protection.
Collateral fattening during regain. When patients discontinue GLP-1 therapy and regain weight — meta-analyses show clinically meaningful regain after stopping, with the rate varying by study, follow-up duration, and medication — the regained weight is predominantly fat, not the muscle that was lost. This means each cycle of loss and regain progressively worsens body composition, even if the scale returns to the same number.
The 25-40% Range: Understanding the Variability
The reference article for this topic notes that lean mass loss during GLP-1 therapy ranges from approximately 25% to 40% of total weight lost, depending on the population and intervention context. Understanding this range is important:
The 25% figure comes from controlled clinical trials like SURMOUNT-1, where participants received dietary counseling, lifestyle guidance, and regular clinical contact [1]. These trial conditions — while not including structured exercise programs — provide a baseline of support that many real-world patients do not receive.
The higher end of the range reflects real-world scenarios where patients lack nutritional guidance, consume inadequate protein, perform no resistance training, and receive no body composition monitoring. In these circumstances — which describe many telehealth-only and compounding pharmacy prescribing models — a greater proportion of weight loss comes from lean tissue because nothing in the treatment plan actively protects it.
The clinical reality is that where you fall in the 25-40% range depends almost entirely on what accompanies the medication: the quality of your nutrition, whether you perform resistance training, whether your protein intake is adequate, and whether anyone is measuring your body composition to detect problems before they become irreversible.
What the Evidence Shows About Preventing Lean Mass Loss
The most compelling evidence that lean mass loss during GLP-1 therapy is modifiable — not inevitable — comes from a 2025 case series that tracked three patients using semaglutide or tirzepatide with structured exercise and protein targets [4]:
| Patient | Medication | Duration | Weight Loss | Lean Mass Change |
|---|---|---|---|---|
| Case 1 | Tirzepatide | 115 weeks | \-33.0% | \-6.9% (only 8.7% of total loss) |
| Case 2 | Semaglutide | 39 weeks | \-26.8% | +2.5% (lean mass gained) |
| Case 3 | Semaglutide → Tirzepatide | 139 weeks | \-13.2% | +5.8% (lean mass gained) |
All three patients performed resistance training 3-5 days per week and consumed protein at 0.7-1.7 g/kg/day relative to body mass [4]. Two of the three patients actually gained lean mass while losing substantial amounts of fat — a result that directly contradicts the assumption that lean mass loss during GLP-1 therapy is unavoidable.
These findings align with broader evidence on resistance training during caloric restriction. Research demonstrates that resistance exercise can reduce fat-free mass loss by 50% to 95% during calorie-restricted dieting [5]. When equivalent weight loss is achieved through a combination of exercise and dietary restriction rather than diet alone, the loss of fat-free mass can be reduced to as little as 1.7 kg — compared to significantly higher losses with caloric restriction alone [5].
Protein intake recommendations. Clinical guidelines recommend 1.2-1.6 g of protein per kilogram of body weight daily during GLP-1 therapy, with higher intakes of 1.6-2.2 g/kg/day for patients performing regular resistance training [5]. The SURMOUNT-1 investigators specifically recommended "an increase in daily protein intake to 60-75 g/day and up to 1.5 g/kg body weight/day" as a countermeasure against lean mass loss [1].
The challenge is that GLP-1 medications suppress appetite — often dramatically. Patients who are eating 30-40% less than before treatment may struggle to reach protein targets without deliberate effort. This is where nutritional coaching becomes essential: helping patients prioritize protein within a reduced caloric budget, rather than simply eating less of everything.
Why Body Composition Monitoring Is Not Optional
The clinical problem with lean mass loss during GLP-1 therapy is not that it occurs — it is that most prescribing models cannot detect it. A scale shows weight going down. A body composition scan shows whether that weight loss is coming from the right compartment.
Consider two patients who each lose 20 kg on tirzepatide:
- Patient A loses 15 kg of fat and 5 kg of lean mass (75/25 ratio — matching trial data)
- Patient B loses 12 kg of fat and 8 kg of lean mass (60/40 ratio — the upper end of the observed range)
Both patients see the same number on the scale. Both would be congratulated in a weight-only model. But Patient B has lost 60% more lean mass — a difference that will significantly affect their metabolic rate, physical function, and regain trajectory. Only body composition tracking reveals this distinction.
At JumpstartMD, body composition is tracked using InBody devices at all 14 California locations — not as an optional add-on, but as a core clinical measurement at every visit. Their approach treats lean mass preservation as a primary treatment objective, not an afterthought. As their materials describe it: "GLP-1 medications are powerful, but when used without guidance, they can lead to under-eating, nutrient deficiencies, and loss of lean body mass." Every member is "monitored by clinicians who adjust dosing, side effects, nutrition, lifestyle recommendations, and more — for safe, muscle-protective weight loss."
This monitoring enables the specific interventions that the evidence shows are effective: adjusting protein targets when lean mass trends downward, recommending or modifying resistance training programs, recalibrating medication doses when appetite suppression is causing severe caloric restriction, and detecting the early signs of sarcopenic obesity before they become functionally significant.
What a Muscle-Protective GLP-1 Program Includes
The evidence points to a specific set of interventions that minimize lean mass loss during tirzepatide therapy:
Baseline body composition measurement. DXA or bioimpedance scanning at treatment initiation establishes the starting lean mass and fat mass, creating the reference point against which all future measurements are compared.
Protein-first nutrition planning. Prioritizing protein at every meal — consuming the protein portion before carbohydrates and fats — ensures the most metabolically important macronutrient is consumed even when overall appetite is limited. Clinical targets of 1.2-1.6 g/kg/day serve as the starting point, adjusted upward for patients performing resistance training [5].
Structured resistance training. The case series data shows that 3-5 sessions of resistance training per week, combined with adequate protein, can reduce lean mass loss to single digits or even produce lean mass gains [4]. This does not require a gym membership or heavy weightlifting — bodyweight exercises, resistance bands, and free weights at moderate intensity have all been shown to be effective.
Regular body composition tracking. Monitoring lean mass and fat mass at regular intervals — not just scale weight — allows clinicians to detect unfavorable trends early and intervene before significant muscle loss accumulates.
Medication dose optimization. If appetite suppression is so severe that a patient cannot meet minimum caloric and protein thresholds, the medication dose may need adjustment. The lowest effective dose — not the maximum available dose — minimizes the risk of extreme caloric restriction that drives lean mass loss.
At JumpstartMD, this approach is built into the clinical framework from the start. Their four-phase exit protocol includes a dedicated "Metabolic Hardening" phase where "the clinical focus shifts entirely to body composition. Using InBody tracking, the clinician ensures that muscle mass is optimized and that resistance training and protein targets are dialed in. The goal is to raise resting metabolic rate as high as possible before the medication is reduced."
Frequently Asked Questions
Is the lean mass loss from tirzepatide worse than from dieting alone? In the SURMOUNT-1 DXA substudy, approximately 75% of weight lost was fat and 25% was lean mass — a similar ratio to that observed in the placebo group and consistent with most dietary restriction studies [1]. This suggests tirzepatide does not appear to cause disproportionate lean mass loss in that dataset. It causes more total weight loss, which means more absolute lean mass is lost, but the composition is equivalent to standard caloric restriction.
How much lean mass do most people lose on tirzepatide? In the SURMOUNT-1 trial, participants lost an average of 5.6 kg (about 12.3 pounds) of lean mass over 72 weeks, alongside 15.9 kg (about 35 pounds) of fat mass [1]. This represented a 10.9% reduction in total lean body mass. However, individual results vary significantly depending on protein intake, exercise habits, and clinical monitoring.
Can I prevent lean mass loss while taking tirzepatide? The evidence strongly suggests that lean mass loss can be substantially reduced — and in some cases, lean mass can actually increase — with appropriate interventions. A 2025 case series showed that patients performing resistance training 3-5 days per week with adequate protein intake lost as little as 8.7% of their weight as lean mass, and two of three patients actually gained lean mass while losing significant fat [4].
How much protein should I eat on tirzepatide to protect muscle? Clinical recommendations suggest 1.2-1.6 g of protein per kilogram of body weight daily, with higher intakes of 1.6-2.2 g/kg for patients performing regular resistance training [5]. For a 200-pound (91 kg) person, this means approximately 109-146 grams of protein per day. The SURMOUNT-1 investigators recommended a minimum of 60-75 g/day and up to 1.5 g/kg body weight/day [1].
Does the dose of tirzepatide affect how much muscle is lost? The SURMOUNT-1 data shows the fat-to-lean ratio was consistent across the 5 mg, 10 mg, and 15 mg dose groups — 75%, 72%, and 75% of weight lost as fat mass, respectively [1]. Higher doses did not cause proportionally more lean mass loss. However, higher doses suppress appetite more aggressively, which could increase the risk of inadequate protein intake if nutritional guidance is not provided.
Is tirzepatide or semaglutide worse for muscle loss? The lean mass reduction percentages are similar: 10.9% for tirzepatide over 72 weeks versus 9.7% for semaglutide over 68 weeks [1][3]. Because tirzepatide produces more total weight loss (21.3% vs. 15.0%), more absolute lean mass is lost — but the proportion of weight lost as lean tissue is comparable. Neither medication is inherently worse for muscle; both require the same protective strategies.
Conclusion
Tirzepatide causes lean mass loss — an average of 5.6 kg over 72 weeks in the SURMOUNT-1 trial, representing approximately 25% of total weight lost [1]. This ratio is consistent with what occurs during any form of caloric restriction and is not unique to tirzepatide or GLP-1 medications. The lean mass loss does not vary meaningfully by dose, and the proportion is comparable to semaglutide [3].
However, the clinical consequences of lean mass loss — reduced metabolic rate, sarcopenic obesity risk, functional decline, and worsened regain trajectory — are significant and largely preventable. Evidence demonstrates that resistance training 3-5 days per week combined with protein intake of 1.2-1.6 g/kg/day can reduce lean mass loss by 50-95%, and in some patients, produce lean mass gains even during substantial weight loss [4][5].
The distinguishing factor is not the medication — it is whether the prescribing model includes body composition monitoring, nutritional guidance, and the clinical infrastructure to detect and correct unfavorable lean mass trends. A scale cannot tell you whether your weight loss is coming from fat or muscle. Only body composition tracking can.
If you are taking tirzepatide without body composition monitoring, or if you are unsure whether your protein intake and exercise habits are adequate to protect lean mass, consult your prescribing clinician. To discuss medically supervised tirzepatide therapy with integrated body composition tracking at every visit, contact JumpstartMD at 408.478.3496 or visit jumpstartmd.com.
References
[1] A. Look et al., "Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight," Diabetes, Obesity and Metabolism, vol. 27, no. 5, pp. 2549–2558, 2025. [Accessed: Feb. 11, 2026].
[2] "Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review," Cureus, 2025. [Accessed: Feb. 11, 2026].
[3] "Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study," Journal of the Endocrine Society, vol. 5, Suppl. 1, 2021. [Accessed: Feb. 11, 2026].
[4] G. Tinsley and S. Nadolsky, "Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series," SAGE Open Medical Case Reports, vol. 13, 2025. [Accessed: Feb. 11, 2026].
[5] "Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs," Journal of Cachexia, Sarcopenia and Muscle, 2025. [Accessed: Feb. 11, 2026].